← Back to Search

Protease Inhibitor

Intensive Antiretroviral Therapy for HIV/AIDS in Infants

Phase 1 & 2
Recruiting
Research Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Mothers will be eligible to enroll with EITHER: Presumed HIV infection defined as greater than or equal to one positive rapid HIV antibody test obtained in the peripartum period. Maternal infection must be confirmed, with confirmatory results available within 10 business days of enrollment. OR Confirmed HIV infection defined as positive results from two samples collected at different time points. All samples tested must be whole blood, serum or plasma. Willing and able to provide written informed consent for participation of herself and her infant. The mother must be of an age to provide legal informed consent as defined by the country in which she resides. If not, informed consent must be obtained from a legal guardian.
Be younger than 18 years old
Must not have
History of any lymphoproliferative disorder
History of active malignancy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured through week 192
Awards & highlights
No Placebo-Only Group

Summary

This trial will study whether earlier ART treatment can help HIV-infected infants achieve remission.

Who is the study for?
This trial is for HIV-infected infants born to mothers with confirmed or presumed HIV. Infants must be less than 48 hours old, at least 36 weeks gestational age, weigh over 2 kg, and able to take oral medication. Mothers should not have received antiretrovirals during pregnancy but may have during labor.
What is being tested?
The study tests early intensive antiretroviral therapy (ART) in newborns using drugs like Nevirapine, Lopinavir/Ritonavir, Raltegravir, VRC01 and NRTIs to see if it can induce HIV remission—meaning the virus becomes undetectable by standard tests.
What are the potential side effects?
Potential side effects from ART medications include digestive issues, rash or allergic reactions, liver problems and changes in blood sugar or fat levels. In infants specifically, close monitoring is needed due to their developing organs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a mother with confirmed or presumed HIV, willing to consent for me and my infant.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a condition where my lymphocytes grow abnormally.
Select...
I have a history of cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured through week 192
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured through week 192 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants who achieve HIV remission
Secondary study objectives
Frequency of Grade 3 or higher adverse events possibly, probably or definitely related to any component of the study regimen
Number of infants meeting the selected eligibility criteria for treatment interruption among infants who also met the viral suppression criteria for treatment interruption.
Number of participants meeting all eligibility criteria for treatment interruption
+2 more
Other study objectives
Change in DTG concentration among treated neonates and young infants
Change in HIV-specific immune response
Change in VRC07-523LS concentration among treated neonates and young infants
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

7Treatment groups
Experimental Treatment
Group I: Cohort 2, Regimen 2R: 2 NRTIs + NVP + RALExperimental Treatment3 Interventions
Participants will receive 2 NRTIs + NVP + RAL.
Group II: Cohort 2, Regimen 1L: 2 NRTIs + NVP + LPV/rExperimental Treatment3 Interventions
Participants will receive 2 NRTIs + NVP + LPV/r.
Group III: Cohort 1, Regimen 3RDV7: 2 NRTIs + NVP + RAL + VRC07-523LS switch to 2 NRTIs + DTG + VRC07-523LSExperimental Treatment4 Interventions
Participants will receive 2 NRTIs + NVP + RAL + VRC07-523LS with subsequent switch to 2 NRTIs + DTG + VRC07-523LS upon reaching 28 days of age and 3 kg body weight.
Group IV: Cohort 1, Regimen 3RD: 2 NRTIs + NVP + RAL switch to 2 NRTIs + DTGExperimental Treatment4 Interventions
Participants will receive 2 NRTIs + NVP + RAL with subsequent switch to 2 NRTIs + DTG upon reaching 28 days of age and 3 kg body weight.
Group V: Cohort 1, Regimen 2RV: 2 NRTIs + NVP + RAL + VRC01Experimental Treatment4 Interventions
Participants will receive 2 NRTIs + NVP + RAL + VRC01.
Group VI: Cohort 1, Regimen 2R: 2 NRTIs + NVP + RALExperimental Treatment3 Interventions
Participants will receive 2 NRTIs + NVP + RAL.
Group VII: Cohort 1, Regimen 1L: 2 NRTIs + NVP + LPV/rExperimental Treatment3 Interventions
Participants will receive 2 NRTIs + NVP + LPV/r.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lopinavir/Ritonavir (LPV/r)
2012
Completed Phase 3
~230
VRC01
2016
Completed Phase 2
~5040
Nevirapine (NVP)
2004
Completed Phase 3
~1920
Raltegravir (RAL)
2002
N/A
~170
DTG
2017
Completed Phase 3
~2530
VRC07-523LS
2019
Completed Phase 2
~390
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
2019
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,933 Previous Clinical Trials
2,740,358 Total Patients Enrolled
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,067 Previous Clinical Trials
2,746,324 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor
3,335 Previous Clinical Trials
5,381,684 Total Patients Enrolled
Yvonne Bryson, MDStudy ChairUniversity of California, Los Angeles
1 Previous Clinical Trials
2 Total Patients Enrolled
Ellen Chadwick, MDStudy ChairNorthwestern University Feinberg School of Medicine and Ann & Robert Lurie Children's Hospital of Chicago
Jennifer Jao, MDStudy ChairNorthwestern University Feinberg School of Medicine and Ann & Robert Lurie Children's Hospital of Chicago
1 Previous Clinical Trials
1,920 Total Patients Enrolled

Media Library

Lopinavir/Ritonavir (Protease Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02140255 — Phase 1 & 2
HIV/AIDS Research Study Groups: Cohort 1, Regimen 3RD: 2 NRTIs + NVP + RAL switch to 2 NRTIs + DTG, Cohort 1, Regimen 3RDV7: 2 NRTIs + NVP + RAL + VRC07-523LS switch to 2 NRTIs + DTG + VRC07-523LS, Cohort 1, Regimen 2R: 2 NRTIs + NVP + RAL, Cohort 1, Regimen 2RV: 2 NRTIs + NVP + RAL + VRC01, Cohort 2, Regimen 1L: 2 NRTIs + NVP + LPV/r, Cohort 1, Regimen 1L: 2 NRTIs + NVP + LPV/r, Cohort 2, Regimen 2R: 2 NRTIs + NVP + RAL
HIV/AIDS Clinical Trial 2023: Lopinavir/Ritonavir Highlights & Side Effects. Trial Name: NCT02140255 — Phase 1 & 2
Lopinavir/Ritonavir (Protease Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02140255 — Phase 1 & 2
~266 spots leftby Jan 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top